These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2081137)

  • 1. The role of serotonin in cardiovascular diseases and their treatment.
    van Zwieten PA; Blauw GJ; van Brummelen P
    Cardiovasc Drugs Ther; 1990 Dec; 4(6):1443-7. PubMed ID: 2081137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs.
    van Zwieten PA; Blauw GJ; van Brummelen P
    Clin Physiol Biochem; 1990; 8 Suppl 3():1-18. PubMed ID: 2132170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiological relevance of serotonin.
    van Zwieten PA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S19-25. PubMed ID: 2446063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonergic receptors and drugs in hypertension.
    van Zwieten PA; Blauw GJ; van Brummelen P
    Pharmacol Toxicol; 1992 Jun; 70(6 Pt 2):S17-22. PubMed ID: 1354865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 5-hydroxytryptamine system of blood platelets: physiology and pathophysiology.
    Pletscher A
    Int J Cardiol; 1987 Feb; 14(2):177-88. PubMed ID: 3818134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin and the vascular system. Role in health and disease, and implications for therapy.
    Houston DS; Vanhoutte PM
    Drugs; 1986 Feb; 31(2):149-63. PubMed ID: 3512233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.
    Frishman WH; Huberfeld S; Okin S; Wang YH; Kumar A; Shareef B
    J Clin Pharmacol; 1995 Jun; 35(6):541-72. PubMed ID: 7665716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age, platelet serotonin kinetics and 5HT2-receptor blockade in essential hypertension.
    Amstein R; Fetkovska N; Bühler FR
    J Hum Hypertens; 1990 Aug; 4(4):441-4. PubMed ID: 2258891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.
    Sharif NA
    Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R; Fetkovska N; Pletscher A; Bühler FR
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serotoninergic receptors and cardiovascular diseases].
    Hong E; Castillo C; Flores E; Mercedes F
    Gac Med Mex; 1994; 130(3):131-3. PubMed ID: 7657075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin-activated signal transduction via serotonin receptors on Jurkat cells.
    Aune TM; Kelley KA; Ranges GE; Bombara MP
    J Immunol; 1990 Sep; 145(6):1826-31. PubMed ID: 2144010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age and 5HT 2-receptor blockade with ketanserin in essential hypertension.
    Bühler FR; Amstein R
    Rev Port Cardiol; 1989 Sep; 8(9):621-4. PubMed ID: 2698721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin and the heart.
    Frishman WH; Grewall P
    Ann Med; 2000 Apr; 32(3):195-209. PubMed ID: 10821327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular remodeling and the peripheral serotonergic system.
    Ayme-Dietrich E; Aubertin-Kirch G; Maroteaux L; Monassier L
    Arch Cardiovasc Dis; 2017 Jan; 110(1):51-59. PubMed ID: 28017279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.
    Leonhardt S; Gorospe E; Hoffman BJ; Teitler M
    Mol Pharmacol; 1992 Aug; 42(2):328-35. PubMed ID: 1355262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs.
    Robertson JI
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S48-53. PubMed ID: 1717773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity.
    van Zwieten PA; Blauw GJ; van Brummelen P
    Drugs; 1990; 40 Suppl 4():1-8; discussion 28-30. PubMed ID: 1982649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic activation of 5HT1A and 5HT2 receptors modulates sexually dimorphic communication signals in the weakly electric fish Apteronotus leptorhynchus.
    Smith GT; Combs N
    Horm Behav; 2008 Jun; 54(1):69-82. PubMed ID: 18336816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin (5HT) and its antagonists: involvement in the cardiovascular system.
    Marwood JF; Stokes GS
    Clin Exp Pharmacol Physiol; 1984; 11(5):439-55. PubMed ID: 6098391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.